An Open Label Pilot Study of the NovoTTF-100L(O) System (NovoTTF Therapy) (200 kHz) Concomitant With Weekly Paclitaxel for Recurrent Ovarian Carcinoma

Trial ID # NCT02244502; INNOVATE-3
Phase II
Drug Class Cell Cycle Inhibitors: Other
Drug Name TTfields
Alternate Drug Names NovoTTF-100L(O)
Drugs in Trial Paclitaxel, TTfields
Eligible Participant

Platinum resistant ovarian cancer

Patients Enrolled

31, median 4 prior therapies (1-11); 16% w/ prior bevacizumab

Therapy Setting


Study Design

Open-Label, Non-randomized


ORR, PFS, evaluated per RECIST


ORR: 25% (7PR, n=28)
DCR: 71% (7PR, 13SD, n=28)
PFS: 8.9 months
PFS (6 months): 81% 

Clinically Significant Adverse Events

Serious AE: none related to TTfields
Grade 3-4 AE: none related to TTfields
Skin toxicity (rash or irritation) related to TTfields were seen in 90% (mostly Grade 1-2)


TTfields in combination with weekly paclitaxel is well tolerated and shows encouraging responses


Vergote I et al. Tumor Treating Fields in combination with paclitaxel in recurrent ovarian carcinoma: Results of the INNOVATE pilot study.
Gynecol Oncol (2018) 150(3):471-477

Contact Us
Contact Us

We are here to help! Send us a message below or give us a call at (858) 657-0282.